83280-65-3
Chemical Structure
Napabucasin
Synonym(s): BBI608; BB608
- CAS No.: 83280-65-3
- Formula:C14H8O4
- Molecular Weight:240.21
IUPAC Name: 2-acetylnaphtho[2,3-b]furan-4,9-dione
InChIKey: DPHUWDIXHNQOSY-UHFFFAOYSA-N
SMILES: O=C(C1=C2OC(C(C)=O)=C1)C3=C(C2=O)C=CC=C3
Biological Activity: Napabucasin (BBI608; BB608) is an orally active STAT3 inhibitor. Napabucasin inhibits STAT3/RelA signaling and induces cancer cell apoptosis, cell cycle arrest, and ROS/DNA damage, inhibiting cancer cell proliferation, migration, and invasion. Napabucasin, upon activation by NQO1/POR, enhances Docetaxel (HY-B0011) sensitivity and inhibits BCR-ABL1-positive leukemia self-renewal. Napabucasin recruits cytotoxic T/B lymphocytes, enhances immune checkpoint blockade, prevents liver metastasis, and radiosensitizes diffuse midline glioma. Napabucasin can be used in research on cancers such as glioblastoma, pancreatic ductal adenocarcinoma, and prostate cancer[1][2][3][4][5][6][7].
| Cat. No. | Product Name | Purity | Description | Pricing | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
Napabucasin | 99.94% | Napabucasin (BBI608; BB608) is an orally active STAT3 inhibitor. Napabucasin inhibits STAT3/RelA signaling and induces cancer cell apoptosis, cell cycle arrest, and ROS/DNA damage, inhibiting cancer cell proliferation, migration, and invasion. Napabucasin, upon activation by NQO1/POR, enhances Docetaxel (HY-B0011) sensitivity and inhibits BCR-ABL1-positive leukemia self-renewal. Napabucasin recruits cytotoxic T/B lymphocytes, enhances immune checkpoint blockade, prevents liver metastasis, and radiosensitizes diffuse midline glioma. Napabucasin can be used in research on cancers such as glioblastoma, pancreatic ductal adenocarcinoma, and prostate cancer. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
-
Similarity Score 0.86
HY-159573Napabucasin analogue -
Similarity Score 0.73
HY-N12320Majoranaquinone -
Similarity Score 0.67
HY-N10472STAT3-IN-14 -
Similarity Score 0.67
HY-W031757RAnthraquinone-2-carboxylic acid (Standard) -
Similarity Score 0.65
HY-N1739RTectoquinone (Standard) -
Similarity Score 0.64
HY-N75022-(Hydroxymethyl)anthraquinone -
Similarity Score 0.64
HY-N71602-Hydroxy-3-methylanthraquinone -
Similarity Score 0.63
HY-N7307Pachybasin -
Similarity Score 0.63
HY-124508Lambertellin -
Explore the MedChemAI to find more analogs
References
- [1]. Han D, et al. Napabucasin, a novel STAT3 inhibitor suppresses proliferation, invasion and stemness of glioblastoma cells. Journal of experimental & clinical cancer research : CR. 2019 Jul 05;38(1):289. [Content Brief]
- [2]. Froeling FEM, et al. Bioactivation of Napabucasin Triggers Reactive Oxygen Species-Mediated Cancer Cell Death. Clinical cancer research : an official journal of the American Association for Cancer Research. 2019 Dec 01;25(23):7162-7174.
- [3]. Zhang Y, et al. Suppression of prostate cancer progression by cancer cell stemness inhibitor napabucasin. Cancer medicine. 2016 Jun;5(6):1251-8. [Content Brief]
- [4]. Feng Q, et al. A redox-responsive nanosystem to suppress chemoresistant lung cancer through targeting STAT3. Journal of controlled release : official journal of the Controlled Release Society. 2023 Nov;363:349-360.
- [5]. Wang Q, et al. Napabucasin transforms liver microenvironment and boosts immunotherapy efficacy by converting potential metastases into “hot” tumors. Interdisciplinary Medicine. 2026 May;4(3):e70089.
- [6]. Tauchi T, et al. Activity of the Stemness Inhibitor, BBI608, on the Self-Renewal of BCR-ABL1 Positive Leukemia Cells: Molecular Mechanisms. Blood. 2014 Dec 6;124(21):905.
- [7]. Gallitto M, et al. Targeted delivery of napabucasin with radiotherapy improves outcomes in diffuse midline glioma. Neuro-oncology. 2025 Mar 07;27(3):795-810.
